A dhfr-ts- Leishmania major Knockout Mutant Cross-protects against Leishmania amazonensis

Memorias do Instituto Oswaldo Cruz

Volumn 94, Issue 4, 1999, Pages 491-496

  Veras, P S T ^a   Brodskyn, C I ^b   Balestieri, F M P ^c   De Freitas, L A R ^a   Ramos, A P S ^a   Queiroz, A R P ^b   Barral, A ^b   Beverley, S M ^d   Barral Netto, M ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^c FEDERAL UNIVERSITY OF PARAÍBA   (Brazil)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Auxotrophic Leishmania major; Cross protection; Immunization; Leishmania amazonensis

Indexed keywords

ANIMALIA; LEISHMANIA AMAZONENSIS; LEISHMANIA MAJOR;

DIHYDROFOLATE REDUCTASE; MULTIENZYME COMPLEX; PARASITE ANTIGEN; PROTOZOAL VACCINE; THYMIDYLATE SYNTHASE; THYMIDYLATE SYNTHASE DIHYDROFOLATE REDUCTASE; THYMIDYLATE SYNTHASE-DIHYDROFOLATE REDUCTASE;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; COMPARATIVE STUDY; IMMUNOLOGY; LEISHMANIA MAJOR; MOUSE; MOUSE MUTANT; SKIN LEISHMANIASIS;

ANIMALS; ANTIGENS, PROTOZOAN; LEISHMANIA MAJOR; LEISHMANIASIS, CUTANEOUS; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; MICE, MUTANT STRAINS; MULTIENZYME COMPLEXES; PROTOZOAN VACCINES; TETRAHYDROFOLATE DEHYDROGENASE; THYMIDYLATE SYNTHASE;

EID: 0033159171     PISSN: 00740276     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0074-02761999000400011     Document Type: Article

References (28)

1. Afonso LCC, Scharton TM, Vieira LQ, Wysocka M, Trinchieri G, Scott P 1994. The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science 263: 235-237.
2. Alexander J, Blackwell JM 1986. The immunological significance of genetically determined cross reactivity between taxonomically distinct Leishmania species, p. 185-191. In Leishmania. Taxonomie et Phylogenèse. Applications éco-épidémiologiques, IMEEE, Montpellier.
3. Alexander J, Phillips RS 1978. Leishmania tropica and Leishmania mexicana: cross-immunity in mice. Exp Parasitol 45: 93-100.
4. Barral A, Pedral SD, Grimaldi Jr G, Momen H, MacMahon PD, Ribeiro DJA, Almeida R, Badaró R, Barral-Netto M, Carvalho EM, Johnson WJ 1991. Leishmaniasis in Bahia, Brazil: evidence that Leishmania amazonensis produces a wide spectrum of clinical disease. Am J Trop Med Hyg 44: 536-546.
5. Barral A, Petersen EA, Sacks DL, Neva FA 1983. Late metastatic leishmaniasis in mouse. A model for mucocutaneous disease. Am J Trop Med Hyg 32: 277-285.
6. Barral-Netto M, Barral A 1987. Imunização específǐca nas leishmanioses tegumentares. Mem Inst Oswaldo Cruz 82: 293-302.
7. Belosevic M, Finbloom DS, Van der Meide PH, Slayter MV, Nacy CA 1989. Administration of monoclonal anti-IFN-γ antibodies in vivo abrogates natural resistance of C3H/HeN mice to infection with Leishmania major. J Immunol 143: 266-274.
8. Bogdan C, Gessner A, Solbach W, Rolinghoff M 1996. Invasion, control and persistence of leishmania parasites. Cur Opinion Immunol 8: 517-625.
9. Carvalho EM, Badaró R, Reed SG, Jones TC, Johnson WJ 1985a. Absence of gamma interferon and interleukin 2 production during active visceral leishmaniasis. J Clin Invest 76: 2066-2069.
10. Carvalho EM, Johnson WD, Barreto E, Marsden PD, Costa JLM, Reed SG, Rocha H 1985b. Cell mediated immunity in American cutaneous and mucosal leishmaniasis. J Immunol 135: 4144-4148.
11. Connell ND, Medina-Acosta E, McMaster WR, Bloom BR, Russell DG 1993. Effective immunization against cutaneous leishmaniasis with recombinant bacille Calmette-Guérin expressing the leishmania surface proteinase gp63. Proc Nat Acad Sci USA 90: 11473-11477.
12. Cruz A, Beverley SM 1990. Gene replacement in parasitic protozoa. Nature 348: 171-173.
13. Cruz A, Coburn CM, Beverley SM 1991. Double targeted gene replacement for creating null mutants. Proc Nat Acad Sci USA 88: 7170-7174.
14. Desjeux P 1992. Human leishmaniasis: epidemiology and public health aspects. World Health Statis Quant 45: 267-275.
15. Grimaldi Jr G 1995. Meeting on vaccine studies towards the control of leishmaniasis. Mem Inst Oswaldo Cruz 90: 553-556.
16. Handman E 1997. Leishmania vaccines: old and new. Parasitol Today 13: 236-238.
17. Handman E, Hocking RE, Mitchell GF, Spithill TW 1983. Isolation and characterization of infective and non-infective clones of Leishmania tropica. Mol Biochem Parasitol 7: 111-126.
18. Howard JG, Hale C, Liew FY 1981. Immunological regulation of experimental cutaneous leishmaniasis. IV. Prophylactic effect of sublethal irradiation as a result of abrogation of suppressor T cell generation in mice genetically susceptible to Leishmania tropica. J Exp Med 153: 551-568.
19. Howard JG, Nicklin S, Hale C, Liew FY 1982. Prophylactic immunization against experimental leishmaniasis: I. Protection induced in mice genetically vulnerable to fatal Leishmania tropica infection. J Immunol 132: 450-455.
20. + T cells which protect susceptible BALB/c mice against infection with virulent L. major. Inf Immun 61: 5205-5213.
21. Lainson R, Shaw JJ 1977. Leishmaniasis in Brazil. XII. Observations on cross-immunity in monkeys and man infected with Leishmania mexicana mexicana, L. m. amazonensis, L. braziliensis braziliensis, L. b. guyanensis and L. b. panamensis. J Trop Med Hyg 80: 29-35.
22. + T cells intructs Th2 development and susceptibility to Leishmania major in BALB/c mice. Immunity 6: 541-549.
23. Marchand M, Dadout S, Titus RG, Louis J, Boon T 1987. Variants with reduced virulence derived from Leishmania major after mutagen treatment. Par Immunol 9: 81-92.
24. Mitchell GF, Handman E, Spithill TW 1984. Vaccination against cutaneous leishmaniasis in mice using nonpathogenic cloned promastigotes ofLeishmania major and importance of route of injection. Aust J Exp Biol Med Sci 62: 145-153.
25. Modabber F 1990. Development of vaccines against leishmaniasis. Scand J Infect Diseases 76 (Supp.): 72-78.
26. Romagnani S 1996. Understanding the role of Th1/Th2 cells in infection. Trends Microbiol 4: 470-473.
27. Rivier D, Shah R, Bovay P, Mauel J 1993. Vaccine development against cutaneous leishmaniasis. Subcutaneous administration of radioattenuated parasites protects CBA mice against virulent Leishmania major challenge. Par Immunol 15: 75-84.
28. Titus RG, Gueiros-Filho F, de Freitas LAR, Beverley SM 1995. Development of a safe live leishmania vaccine line by gene replacement. Pmc Nat Acad Sci USA 92: 10267-10271.